ZTS— AI Stock Forecast & Price Targets
Published 8/5/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live ZTS price forecast →
Zoetis is a best-in-class animal health franchise (37% op margin, 67% ROE, $1.78B FCF) trading at ~10x forward EPS after a −50% YoY drawdown, now consolidating at $76 into a binary Q2 print on Aug 6. The setup is objectively cheap and sentiment is washed out, but the tape has repeatedly rejected bounces, margins are compressing sequentially, and the aggressive Kronos snap-back forecast has ~40% MAPE with no directional edge over baseline — patience past earnings has historically been the better trade on this name.
Do NOT add size into Aug 6 BMO earnings — this is a binary event on a name that has repeatedly punished pre-print positioning. If already long, hold core; if flat, wait for the print and the first 1–2 sessions of price discovery. Key levels: hold above $74 keeps the base intact; a beat/reclaim of $78–80 opens the $85–88 gap; a miss with break of $71.47 invalidates the base and opens $65–68. Fade any pre-print squeeze; do not chase the model's $97 target — it has ~45% error and sub-baseline directional accuracy at short horizons.
1–6 months: Constructive if Q2 delivers stable US companion-animal commentary, margin floor near 36–37%, and early Lenivia/Portela uptake data. In that scenario a re-rate to 12–13x forward EPS ($7.39 fwd EPS) supports $88–92. Downside scenario is another guide-down that breaks the $72 base and drags the stock to $65 (~9x forward). Catalysts: Q2 print, Lenivia/Portela script data, VitalRADS closing, capital-allocation commentary (a buyback pause to repair equity would be a bullish tell). What changes my mind: a clean beat with US companion-animal returning to flat/positive and management explicitly repricing the growth algorithm — that would justify moving from HOLD to ACCUMULATE.
1–3 years: The franchise economics (70%+ gross, 37% op margin, 67% ROE, $1.78B FCF) do not disappear at this multiple; if the pipeline (renal mAb 2027, oncology, GLP-1/obesity, cardiology) delivers even 2 of 12 candidates and companion-animal cyclicals normalize, EPS power of $9–10 by 2028 at a 15–18x multiple implies $135–180 — meaningful multi-year upside from $76. Terminal thesis: a durable animal-health compounder re-emerging from a cyclical/competitive reset. Biggest structural risk: the debt-funded buyback strategy has hollowed the equity base to $3.2B against $9.2B debt — another leg down in earnings pressures credit metrics, and the class-action litigation around Librela/Simparica Trio/Apoquel/Cytopoint demand is a tail risk that could materially reprice sentiment if disclosure widens.
Unit economics remain elite — 71.8% gross margin, 36.6% operating margin, 67% ROE, 21% ROIC, and $1.78B FCF on $9.53B revenue — but the sequential trajectory is deteriorating: revenue has stepped down four quarters running ($2.46B Q2'25 → $2.40B Q3'25 → $2.39B Q4'25 → $2.26B Q1'26), and operating income has compressed from $989M in Q2'25 to $822M in Q1'26 (op margin from 40.2% to 36.3%). The balance sheet is the ugly line item: $9.24B total debt vs $3.23B equity (D/E 2.86x), and stockholders' equity actually contracted from $5.40B to $3.23B in two quarters as debt-funded buybacks hollowed out the capital base. Valuation is undeniably compressed at 12.6x trailing / 10.3x forward P/E and PEG 1.39, with a 2.75% dividend yield and 33.7% payout providing a floor. The bullish EPS-estimate revision (next-year growth 7.1% → 12.2%) is the first positive fundamental delta in months, but it must be validated by Thursday's print. This remains a high-quality franchise being punished for cyclical/competitive weakness, not a broken business — but it's not yet demonstrably stabilizing.
Across timeframes the picture is a classic post-capitulation base with a heavy overhead structure. The weekly chart shows a 52% drawdown from $160 highs with price now pinned at $76 near the 52-week low of $71.47 (only 6.4% above the low, 52.6% below the high). The daily chart shows a tight $72–$80 range building since early May after the gap-down, with SMA20 essentially flat (+0.21%) and SMA50 marginally overhead (−1.31%), while SMA200 sits ~31% above — the long-term downtrend is intact and untested. The 1h chart shows price rolling from $78 back to $76 (RSI 47.3, neutral), with the model projecting an implausible snap to $97 then reversion — a pattern this model has consistently overshot on. The 4h and daily forecasts push toward $119–$121 within weeks, which is inconsistent with the 45% MAPE and the fact that every prior bounce ($100+ targets) has failed to print. Concrete levels: support at $74/$72 (base) and $71.47 (52-wk invalidation); resistance at $78 (SMA50), then the May breakdown gap near $88, with $100 the psychological ceiling. Momentum is neutral, not accumulative.
The signal item is Barchart's 'Bull Case for Zoetis as Michael Burry Doubles Down' (Aug 3) combined with Simply Wall St's coverage of Burry increasing his position — a notable value-oriented endorsement that aligns with the compressed multiple. Balanced against that, one analyst price target was cut 14.15% to $108.07, and the Zacks/Yahoo Q2 preview pieces flag competitive pressures and safety concerns around companion-animal OA products even as the 12-candidate pipeline (including Lenivia/Portela OA mAbs launched in Canada/EU) advances. Congressional buying (Byron Donalds, small ticket) and 80% bullish retail sentiment on Stocktwits skew contrarian-positive but are low-signal. The dominant near-term catalyst is Wednesday's BMO Q2 print (Aug 6) — everything else is context. Broader tape news (CVS, Zimmer, Bloomin' guides) is unrelated noise.
- Lenivia (canine) and Portela (feline) OA monoclonal antibody launches (July 22) — competitive response to entrenched anti-NGF category; early Canada/EU uptake is the key mid-term proof point
- 12-candidate pipeline including renal mAb (2027), oncology, cardiology, and GLP-1/obesity for companion animals — first material readouts in 2026–2027
- VitalRADS diagnostics acquisition (~$160M, H2'26) deepens diagnostics segment, which is more insulated from pharma-cyclical companion-animal weakness
- Next-year EPS growth estimate revision from 7.1% → 12.2% (+5.1pp) signals sell-side is starting to price in operational stabilization
- Pricing power intact in parasiticides (Simparica Trio) and dermatology (Apoquel/Cytopoint) core franchises supports 70%+ gross margins through the reset
- Aug 6 Q2 print is binary: another guide-down would break $72 base support and re-open $65 downside
- Balance sheet strain — $9.24B debt vs $3.23B equity (D/E 2.86x), with equity contracting $2.2B in two quarters from debt-funded buybacks
- Class-action litigation alleging overstated Librela/Simparica Trio/Apoquel/Cytopoint demand — quantifiable overhang with disclosure risk
- US companion-animal secular weakness (−8% YoY in Q1) driven by clinic traffic and pricing sensitivity — not clearly cyclical
- Competitive erosion in OA anti-NGF category; Lenivia share-take vs entrenched competitor is unproven
- SMA200 sits ~31% overhead; long-term downtrend intact and prior technical support bounces have consistently failed
- Sequential margin compression: Q1'26 op margin 36.3% vs Q2'25 40.2% — trajectory not yet stabilized
- Forecast model shows extreme bullish snap-back ($97–$121) but has 40–45% MAPE with no directional edge over naive baseline — heavily discount
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord